It exhibits a molecularly targeted therapeutic approach by targeting and inhibiting several pathways, including vascular endothelial growth factor receptor-2 (VEGFR-2), platelet-derived growth factor receptor (PDGFR), and extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase–ERK (MEK)/rapidly accelerated fibrosarcoma (RAF), thereby offering antiproliferative, antiangiogenic, and antiapoptotic effects [9,10]. The gene discussed is KDR; the disease is fibrosarcoma.